Clinical Evaluation of a Blood-Based Diagnostic Device Using Raman Spectroscopy and AI to Classify Breast Cancer Risk
Led by EXoPERT · Updated on 2026-09-10
330
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new blood-based test device developed by EXoPERT that uses Raman spectroscopy and artificial intelligence to classify patients at high or low risk for breast cancer. This prospective clinical performance trial aims to confirm the clinical effectiveness and safety of this in vitro diagnostic medical device to assist in breast cancer diagnosis, addressing limitations of current imaging methods and reducing unnecessary biopsies.
The study involves using the test device, called ExoPred, which analyzes extracellular vesicles extracted from human plasma to differentiate between high-risk and low-risk breast cancer patients. Participants include adult females aged 40 or older, diagnosed with breast nodules or breast cancer at specific BI-RADS categories and scheduled for or having undergone biopsy. The trial collects blood samples before treatment or surgery to evaluate the devices diagnostic performance.
Participants will provide clinical information such as tumor size, staging, and family history alongside blood samples. The study measures sensitivity and specificity of the test over an average follow-up of one year. Throughout the trial, researchers monitor diagnostic accuracy and safety while participants undergo routine care. The study period extends until the end of 2026, with ongoing data collection and analysis.
CONDITIONS
Brief Title
A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer
Research Team
J
Jongwon Choi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Voluntary written consent to participate in the study
Confirmed breast cancer or breast nodules through imaging or pathology
Diagnosed prior to treatment and surgery
Lesion classified as BI-RADS category 4, 5, or 6 and biopsy performed or scheduled within 2 weeks
Ability to provide blood samples
Ability to provide clinical information including age, biological sex, breast density, occupational information, tumor or nodule size and staging, family and cancer history, breast-related diseases, and chronic disease history
You will not qualify if you...
Diagnosis of any cancer (malignant tumor) within 5 years prior to consent with treatment by chemotherapy, radiation, or surgery
Breast cancer due to metastasis from other malignant tumors
Pregnant women
Participation in a drug-related clinical trial within 3 months prior to consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Testing
Duration - Up to 1 year
Participants provide blood samples and clinical information before treatment or surgery to evaluate the new diagnostic device.
Periodic visits as needed for data collection
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Clinical Evaluation of a Blood-Based Diagnostic Device Using Raman Spectroscopy and AI to Classify Breast Cancer Risk
Phase 1 Trial of Oral MBQ-167 for Advanced Breast Cancer Evaluating Dose and Safety
Phase II Study of Early Clinical Response to Predict Surgery Outcome in Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy
Comparing Cryoablation and Breast Surgery for Early-Stage Breast Cancer Treatment
Phase 3 Study of Local Tumor Control and Cost Analysis
Cryoablation Compared to Lumpectomy for Early Stage T1 Breast Cancer in Women
A Randomized Trial Assessing Safety and Disease Control
Testing an Arabic AI Mobile App to Support Women with Breast Cancer During Chemotherapy
A Randomized Study Comparing the App Plus Usual Care to Usual Care Alone
Fudan University Breast Cancer Neoadjuvant Therapy Precision Study Using Novel and Standard Treatments
Evaluating a 6-Month Adapted Physical Activity Program for Women Undergoing Active Breast Cancer Treatment to Improve Quality of Life and Reduce Costs
Evaluation of HydroMARK Plus Breast Biopsy Site Marker Retrieval Success Compared to HydroMARK and Surgeon Satisfaction Assessment
Effect of a Multidisciplinary Lifestyle Intervention on the Exposome of Premenopausal Women With Stage I-III Breast Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Artificial Intelligence-Based Exosome Analysis for Improving Diagnostic Performance of Breast Lesions on Ultrasound: Protocol of a Prospective, Multicenter Cohort Study.